Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Serotonin Syndrome 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroendocrine Tumors 1Hysterectomies for Low- or Intermediate-risk Endometrial Carcinoma 1Esophageal Squamous Cell Carcinoma 1Carcinoid Tumors, Intestinal 1Carcinoid Tumor 1Breast Neoplasms 1

Interventions

Cyclophosphamide 409Methotrexate 246Cytarabine 231Vincristine 188fludarabine phosphate 172Dexamethasone 169fludarabine 143Etoposide 143Peripheral Blood Stem Cell Transplantation 136Filgrastim 132Whole-Body Irradiation 116Mycophenolic Acid 115Busulfan 112Doxorubicin 109Tacrolimus 106Mercaptopurine 106Cyclosporine 95Radiotherapy 93Melphalan 93Rituximab 90pegaspargase 88Prednisone 85Asparaginase 84Daunorubicin 82Granulocyte Colony-Stimulating Factor 74blinatumomab 72Antilymphocyte Serum 71Calcium Dobesilate 69Clofarabine 58Thiotepa 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Random Allocation × Clear all
NCT06860269 2026-02-10

GRAALL-2024

Assistance Publique - Hôpitaux de Paris

Phase 2/3 Recruiting
1,200 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡